Advacan

Biocon offers a wide range of nephrology which includes advacan. Composition: each uncoated /coated tablet contains everolimus 0.5mg and 0.25mg. Mechanism of action: everolimus, a proliferation signal inhibitor, prevents allograft rejection in allotransplantation. It exerts its immunosuppressive effect by inhibiting the proliferation, and thus clonal expansion, of antigen-activated t cells which is driven by t cell-specific interleukins, e.g. Interleukin-2 and interleukin-15. Indications: it is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk, receiving an allogeneic renal or cardiac transplant. Advacan should be used in combination with cyclosporine and corticosteroids